Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Human Pathology

• Publication date

  2006-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.HUMPATH.2006.05.002PMID 16949925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2005

  2005cited by this paper
• Expression of urokinase plasminogen activator, its receptor and type‐1 inhibitor in malignant and benign prostate tissue

  2005cited by this paper
• Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.

  2004cited by this paper
• The urokinase plasminogen activator system: role in malignancy.

  2004cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis

  2002cited by this paper
• In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen

  2002cited by this paper
• Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.

  2001cited by this paper
• The role and regulation of urokinase‐type plasminogen activator receptor gene expression in cancer invasion and metastasis

  2001cited by this paper
• The urokinase plasminogen activator system as a novel target for tumour therapy

  2000cited by this paper
• The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

  2000cited by this paper
• Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.

  2000cited by this paper
• Natural history of progression after PSA elevation following radical prostatectomy.

  1999cited by this paper
• Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

  1999cited by this paper
• Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer.

  1999cited by this paper
• Elevation of serum levels of urokinase‐type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

  1999cited by this paper
• Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.

  1999cited by this paper
• Metalloproteases and urokinase in angiogenesis and tumor progression.

  1998cited by this paper
• Tissue microarrays for high-throughput molecular profiling of tumor specimens

  1998cited by this paper
• Metalloproteases and urokinase in angiogenesis and tumor progression.

  1998cited by this paper
• High tissue content of urokinase plasminogen activator (u‐PA) is associated with high stromal expression of u‐PA mRNA in poorly differentiated serous ovarian carcinoma

  1998cited by this paper
• The urokinase‐type plasminogen activator system in cancer metastasis: A review

  1997cited by this paper
• Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy

  1997cited by this paper
• Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes

  1997cited by this paper
• uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?

  1997cited by this paper
• Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo

  1997cited by this paper
• Urokinase-type plasminogen activator expression in human prostate carcinomas.

  1996cited by this paper
• Immunohistochemical localization of urokinase‐type plasminogen activator, type‐1 plasminogen‐activator inhibitor, urokinase receptor and α2‐macroglobulin receptor in human breast carcinomas

  1996cited by this paper
• Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.

  1995cited by this paper
• Biological and clinical aspects of plasminogen activator inhibitor type 2.

  1995cited by this paper
• The TNM classification of prostate cancer

  1992cited by this paper
• Plasminogen activator inhibitors: hormonally regulated serpins.

  1990cited by this paper
• Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.

  1985cited by this paper
• Classification of prostatic carcinomas.

  1966cited by this paper

• Non-Surgical Bleeding and Transurethral Resection of the Prostate (TURP) Syndrome after TURP Surgery: A Case Report and Literature Review

  2024cites this paper
• Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator

  2024cites this paper
• Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts

  2023cites this paper
• Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges

  2022cites this paper
• uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study

  2021cites this paper
• Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4–10 ng/mL

  2020cites this paper
• Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial

  2020cites this paper
• Intracerebral Hemorrhaging Due to Coagulopathy Caused by Latent Advanced Prostate Cancer

  2020cites this paper
• A piece in prostate cancer puzzle: Future perspective of novel molecular signatures

  2020cites this paper
• Molecular imaging of proteases in cancer

  2020cites this paper
• The Tumor Microenvironments of Lethal Prostate Cancer.

  2019cites this paper
• 1 Biomarkers of Aggressiveness in Prostate Cancer

  2018cites this paper
• Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients

  2017cites this paper
• Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells

  2017cites this paper
• Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.

  2017cites this paper
• Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.

  2017cites this paper
• Conventional and Promising Biomarkers for Prostate Cancer their Clinical Implication and Prospective Role

  2016cites this paper
• PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives

  2016cites this paper
• Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105

  2016cites this paper
• Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer.

  2016cites this paper
• Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix

  2015cites this paper
• Imaging active urokinase plasminogen activator in prostate cancer.

  2015cites this paper
• Disseminated Intravascular Coagulation as a Result of Metastatic Prostate Cancer: A Case Report

  2015cites this paper
• The source of matrix-degrading enzymes in human cancer: Problems of research reproducibility and possible solutions

  2015cites this paper
• Prostate cancer relevant antigens and enzymes for targeted drug delivery.

  2014cites this paper
• Актуальные вопросы молекулярной диагностики рака предстательной железы

  2014cites this paper
• Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer

  2014cites this paper
• Optimization of proteolytically induced photosensitizers for fluorescence imaging and Photodynamic Therapy

  2014cites this paper
• Molecular Pathology and Diagnostics of Prostate Cancer

  2014cites this paper
• Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer.

  2013cites this paper
• Molecular Mechanisms of Castrate Resistant Prostate Cancer

  2013cites this paper
• Prostate Cancer: Predictive Markers in Clinical Development

  2013cites this paper
• Surface α-Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target

  2013cites this paper
• Surface a -Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target

  2013cites this paper
• Prostate cancer invasion and metastasis: insights from mining genomic data.

  2013cites this paper
• CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer

  2013cites this paper
• Expressão de uPAR na próstata canina normal e com lesões proliferativas

  2013cites this paper
• EXPRESSION IN CANINE NORMAL PROSTATE AND WITH PROLIFERATIVE DISORDERS

  2013cites this paper
• Selective Photodetection and Photodynamic Therapy for Prostate Cancer through Targeting of Proteolytic Activity

  2012cites this paper
• Urokinase‐Type Plasminogen Activator, Its Receptor and Inhibitor as Biomarkers in Cancer

  2012cites this paper
• Conception, élaboration et caractérisation photophysiques et biochimiques de molécules photoactivables pour la thérapie photodynamique

  2012cites this paper
• Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme

  2012cites this paper
• Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report

  2012cites this paper
• Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions

  2012cites this paper
• The role of 8q amplification and microRNAs in prostate cancer

  2012cites this paper
• Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs.

  2012cites this paper
• Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

  2011cites this paper
• Clinical applications of the urokinase receptor (uPAR) for cancer patients.

  2011cites this paper
• Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.

  2011cites this paper
• On the cutting edge: protease-sensitive prodrugs for the delivery of photoactive compounds

  2011cites this paper
• Angiogenesis , Metastasis , and the Cellular Microenvironment Macrophage-Dependent Cleavage of the Laminin Receptor a 6 b 1 in Prostate Cancer

  2011cites this paper
• Macrophage-Dependent Cleavage of the Laminin Receptor α6β1 in Prostate Cancer

  2011cites this paper
• It is all about proteases: from drug delivery to in vivo imaging and photomedicine.

  2011cites this paper
• Biomarkers of Aggressiveness in Prostate Cancer

  2011cites this paper
• Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.

  2011cites this paper
• Molecular pathways in the progression of hormone-independent and metastatic prostate cancer.

  2010cites this paper
• Modulation of photosensitization processes for an improved targeted photodynamic therapy.

  2010cites this paper
• Promising tumor‐associated antigens for future prostate cancer therapy

  2010cites this paper
• SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis

  2010cites this paper
• Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.

  2010cites this paper
• Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• Experimental Therapeutics , Molecular Targets , and Chemical Biology Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis

  2009cites this paper
• The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

  2009cites this paper
• Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.

  2009cites this paper
• Urokinase-plasminogen-activator sensitive polymeric photosensitizer prodrugs: design, synthesis and in vitro evaluation

  2009cites this paper
• Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted α Radioimmunoconjugates

  2009cites this paper
• Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression.

  2009cites this paper
• Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.

  2009cites this paper
• Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.

  2009cites this paper
• Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.

  2009cites this paper
• Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.

  2009cites this paper
• Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.

  2009cites this paper
• Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy

  2008cites this paper
• Protease-sensitive prodrugs: a new strategy for selective Photodynamic Therapy

  2008cites this paper
• Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

  2008cites this paper
• Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor

  2008cites this paper
• Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers

  2008cites this paper
• Differential gene expression in murine large cell B-cell lymphoma metastatic variants.

  2008cites this paper
• The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression

  2008influential citation
• Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy

  2008cites this paper
• Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer.

  2007cites this paper
• The Role of Tissue Microarrays in Prostate Cancer Biomarker Discovery

  2007cites this paper
• Targeting uPA/uPAR in prostate cancer.

  2007cites this paper
• Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases

  2007cites this paper
• Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

  2007cites this paper
• Non-Surgical Bleeding and Transurethral Resection of the Non-Surgical Bleeding and Transurethral Resection of the Prostate (TURP) Syndrome after TURP Surgery: A Case Report Prostate (TURP) Syndrome after TURP Surgery: A Case Report and Literature Review and Literature Review

  year unknowncites this paper
• Lighting up cancer aggressiveness: targeting the urokinase plasminogen activator receptor for intraoperative optical imaging

  year unknowncites this paper
• Lighting up cancer aggressiveness: targeting the urokinase plasminogen activator receptor for intraoperative optical imaging

  year unknowncites this paper
• Lighting up cancer aggressiveness: targeting the urokinase plasminogen activator receptor for intraoperative optical imaging

  year unknowncites this paper